WallStSmart

Doximity Inc (DOCS)vsTempus AI, Inc. Class A Common Stock (TEM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Tempus AI, Inc. Class A Common Stock generates 118% more annual revenue ($1.43B vs $655.57M). DOCS leads profitability with a 25.5% profit margin vs -17.8%. DOCS earns a higher WallStSmart Score of 59/100 (C).

DOCS

Buy

59

out of 100

Grade: C

Growth: 5.3Profit: 8.5Value: 8.0Quality: 8.5
Piotroski: 3/9Altman Z: 5.39

TEM

Avoid

28

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -0.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DOCSUndervalued (+50.3%)

Margin of Safety

+50.3%

Fair Value

$52.21

Current Price

$25.58

$26.63 discount

UndervaluedFair: $52.21Overvalued

Intrinsic value data unavailable for TEM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DOCS6 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.3910/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.6%9/10

Every $100 of equity generates 21 in profit

Profit MarginProfitability
25.5%9/10

Keeps 26 of every $100 in revenue as profit

PEG RatioValuation
0.598/10

Growing faster than its price suggests

Operating MarginProfitability
21.5%8/10

Strong operational efficiency at 21.5%

TEM1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
21.6%8/10

Revenue surging 21.6% year-over-year

Areas to Watch

DOCS3 concerns · Avg: 3.0/10
P/E RatioValuation
29.1x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-51.9%2/10

Earnings declined 51.9%

TEM4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
23.9x2/10

Trading at 23.9x book value

Return on EquityProfitability
-57.2%2/10

ROE of -57.2% — below average capital efficiency

Free Cash FlowQuality
$-18.62M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : DOCS

The strongest argument for DOCS centers on Debt/Equity, Altman Z-Score, Return on Equity. Profitability is solid with margins at 25.5% and operating margin at 21.5%. PEG of 0.59 suggests the stock is reasonably priced for its growth.

Bull Case : TEM

The strongest argument for TEM centers on Revenue Growth. Revenue growth of 21.6% demonstrates continued momentum.

Bear Case : DOCS

The primary concerns for DOCS are P/E Ratio, Piotroski F-Score, EPS Growth.

Bear Case : TEM

The primary concerns for TEM are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 3.25 is elevated, increasing financial risk.

Key Dynamics to Monitor

DOCS profiles as a mature stock while TEM is a growth play — different risk/reward profiles.

TEM carries more volatility with a beta of 3.72 — expect wider price swings.

TEM is growing revenue faster at 21.6% — sustainability is the question.

DOCS generates stronger free cash flow (42M), providing more financial flexibility.

Bottom Line

DOCS scores higher overall (59/100 vs 28/100), backed by strong 25.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Doximity Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.

Tempus AI, Inc. Class A Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.

Visit Website →

Want to dig deeper into these stocks?